Hawes D, Neville A M, Cote R J
Department of Pathology, Keck School of Medicine, University of Southern California/Norris Comprehensive Cancer Center, Los Angeles, California 90033, USA.
Semin Surg Oncol. 2001 Jun;20(4):312-8. doi: 10.1002/ssu.1049.
The most important factor affecting the outcome of patients with invasive cancer is whether the tumor has spread, either regionally (to regional lymph nodes) or systemically. However, a proportion of patients with no evidence of systemic dissemination will develop recurrent disease after primary "curative" therapy. Clearly, these patients had occult systemic spread of disease that was undetectable by routinely employed methods (careful pathological, clinical, biochemical, and radiological evaluation). In addition, the success of adjuvant therapy is assumed to stem from its ability to eradicate occult metastases before they become clinically evident. Therefore, methods for the detection of occult metastases in patients with the earliest stage of cancer, i.e., prior to detection of metastases by any other clinical or pathological analysis, have received a great deal of attention.
影响浸润性癌患者预后的最重要因素是肿瘤是否已发生扩散,无论是局部扩散(至区域淋巴结)还是全身扩散。然而,一部分没有全身播散证据的患者在接受初次“根治性”治疗后会出现疾病复发。显然,这些患者存在隐匿性全身疾病播散,而常规使用的方法(仔细的病理、临床、生化和影像学评估)无法检测到。此外,辅助治疗的成功被认为源于其在隐匿性转移灶出现临床症状之前将其根除的能力。因此,在癌症最早期阶段,即在通过任何其他临床或病理分析检测到转移之前,检测隐匿性转移灶的方法受到了广泛关注。